{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:17:56Z","timestamp":1787239076160,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leukemia Lymphoma Society; International Myeloma Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The plasma cell cancer multiple myeloma (MM) varies significantly in genomic characteristics, response to therapy, and long-term prognosis. To investigate global interactions in MM, we combined a known protein interaction network with a large clinically annotated MM dataset. We hypothesized that an unbiased network analysis method based on large-scale similarities in gene expression, copy number aberration, and protein interactions may provide novel biological insights. Applying a novel measure of network robustness, Ollivier-Ricci Curvature, we examined patterns in the RNA-Seq gene expression and CNA data and how they relate to clinical outcomes. Hierarchical clustering using ORC differentiated high-risk subtypes with low progression free survival. Differential gene expression analysis defined 118 genes with significantly aberrant expression. These genes, while not previously associated with MM, were associated with DNA repair, apoptosis, and the immune system. Univariate analysis identified 8\/118 to be prognostic genes; all associated with the immune system. A network topology analysis identified both hub and bridge genes which connect known genes of biological significance of MM. Taken together, gene interaction network analysis in MM uses a novel method of global assessment to demonstrate complex immune dysregulation associated with shorter survival.<\/jats:p>","DOI":"10.1038\/s41408-023-00935-2","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T21:01:36Z","timestamp":1701291696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-3565","authenticated-orcid":false,"given":"Anish K.","family":"Simhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee H.","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Elkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiening","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Deasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Tannenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"935_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335\u201348.","journal-title":"Nat Rev Cancer"},{"key":"935_CR2","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.2147\/OTT.S205922","volume":"12","author":"Y Hu","year":"2019","unstructured":"Hu Y, Chen W, Wang J. Progress in the identification of gene mutations involved in multiple myeloma. Onco Targets Ther. 2019;12:4075\u201380.","journal-title":"Onco Targets Ther"},{"key":"935_CR3","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"935_CR4","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"935_CR5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020\u20138.","journal-title":"Blood"},{"key":"935_CR6","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","volume":"67","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67:2982\u20139.","journal-title":"Cancer Res"},{"key":"935_CR7","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543\u201353.","journal-title":"Blood"},{"key":"935_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0160-x","volume":"9","author":"JS Jang","year":"2019","unstructured":"Jang JS, Li Y, Mitra AK, Bi L, Abyzov A, van Wijnen AJ, et al. Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer J. 2019;9:2.","journal-title":"Blood Cancer J"},{"key":"935_CR9","doi-asserted-by":"publisher","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Genomic basis of multiple myeloma subtypes from the MMRF CoMMpass study. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.08.02.21261211","DOI":"10.1101\/2021.08.02.21261211"},{"key":"935_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30694-w","volume":"13","author":"M Bustoros","year":"2022","unstructured":"Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13:3449.","journal-title":"Nat Commun"},{"key":"935_CR11","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-11-0596","volume":"17","author":"L Agnelli","year":"2011","unstructured":"Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 2011;17:7402\u201312.","journal-title":"Clin Cancer Res"},{"key":"935_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296\u2013303.","journal-title":"Blood"},{"key":"935_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2015.309","volume":"30","author":"N Weinhold","year":"2016","unstructured":"Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, et al. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016;30:423\u201330.","journal-title":"Leukemia"},{"key":"935_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/leu.2017.197","volume":"32","author":"A Lagan\u00e0","year":"2018","unstructured":"Lagan\u00e0 A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, et al. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia. 2018;32:120\u201330.","journal-title":"Leukemia"},{"key":"935_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep12323","volume":"5","author":"R Sandhu","year":"2015","unstructured":"Sandhu R, Georgiou T, Reznik E, Zhu L, Kolesov I, Senbabaoglu Y, et al. Graph curvature for differentiating cancer networks. Sci Rep. 2015;5:12323.","journal-title":"Sci Rep."},{"key":"935_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41525-021-00259-9","volume":"6","author":"R Elkin","year":"2021","unstructured":"Elkin R, Oh JH, Liu YL, Selenica P, Weigelt B, Reis-Filho JS, et al. Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. NPJ Genom Med. 2021;6:99.","journal-title":"NPJ Genom Med"},{"key":"935_CR17","doi-asserted-by":"publisher","first-page":"1026279","DOI":"10.3389\/fpsyt.2022.1026279","volume":"13","author":"AK Simhal","year":"2022","unstructured":"Simhal AK, Carpenter KLH, Kurtzberg J, Song A, Tannenbaum A, Zhang L, et al. Changes in the geometry and robustness of diffusion tensor imaging networks: secondary analysis from a randomized controlled trial of young autistic children receiving an umbilical cord blood infusion. Front Psychiatry. 2022;13:1026279.","journal-title":"Front Psychiatry"},{"key":"935_CR18","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1182\/blood.V122.21.532.532","volume":"122","author":"JJ Keats","year":"2013","unstructured":"Keats JJ, Craig DW, Liang W, Venkata Y, Kurdoglu A, Aldrich J, et al. Interim analysis of the mmrf commpass trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles. Blood. 2013;122:532\u2013532.","journal-title":"Blood"},{"key":"935_CR19","doi-asserted-by":"publisher","first-page":"D497","DOI":"10.1093\/nar\/gkh070","volume":"32","author":"S Peri","year":"2004","unstructured":"Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004;32:D497\u2013501.","journal-title":"Nucleic Acids Res"},{"key":"935_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139.","journal-title":"Nat Methods"},{"key":"935_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s42003-021-01938-0","volume":"4","author":"EH Rustad","year":"2021","unstructured":"Rustad EH, Nadeu F, Angelopoulos N, Ziccheddu B, Bolli N, Puente XS, et al. Mmsig: A fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Commun Biol. 2021;4:424.","journal-title":"Commun Biol"},{"key":"935_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.","journal-title":"Nat Commun"},{"key":"935_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","volume":"1","author":"EH Rustad","year":"2020","unstructured":"Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020;1:258\u201373.","journal-title":"Blood Cancer Discov"},{"key":"935_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.crma.2007.10.041","volume":"345","author":"Y Ollivier","year":"2007","unstructured":"Ollivier Y. Ricci curvature of metric spaces. C R Math. 2007;345:643\u20136.","journal-title":"C R Math"},{"key":"935_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0377-0427(87)90125-7","volume":"20","author":"PJ Rousseeuw","year":"1987","unstructured":"Rousseeuw PJ. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math. 1987;20:53\u201365.","journal-title":"J Comput Appl Math"},{"key":"935_CR26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289\u2013300.","journal-title":"J R Stat Soc"},{"key":"935_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"935_CR28","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"935_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"935_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"935_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.immuni.2015.12.006","volume":"44","author":"J Godec","year":"2016","unstructured":"Godec J, Tan Y, Liberzon A, Tamayo P, Bhattacharya S, Butte AJ, et al. Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation. Immunity. 2016;44:194\u2013206.","journal-title":"Immunity"},{"key":"935_CR32","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175\u201397.","journal-title":"Stat Med"},{"key":"935_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"935_CR34","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587\u201397.","journal-title":"Blood"},{"key":"935_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019;10:3835.","journal-title":"Nat Commun"},{"key":"935_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bbrc.2019.08.163","volume":"519","author":"RSS Barbosa","year":"2019","unstructured":"Barbosa RSS, Dantonio PM, Guimar\u00e3es T, de Oliveira MB, Fook Alves VL, Sandes AF, et al. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. Biochem Biophys Res Commun. 2019;519:597\u2013604.","journal-title":"Biochem Biophys Res Commun"},{"key":"935_CR37","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","volume":"9","author":"S Mithraprabhu","year":"2014","unstructured":"Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9:1511\u201320.","journal-title":"Epigenetics"},{"key":"935_CR38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2141.2006.06052.x","volume":"133","author":"HS Yeh","year":"2006","unstructured":"Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, et al. Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. Br J Haematol. 2006;133:526\u20139.","journal-title":"Br J Haematol"},{"key":"935_CR39","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2017.345","volume":"32","author":"F Maura","year":"2018","unstructured":"Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, et al. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018;32:1044\u20138.","journal-title":"Leukemia"},{"key":"935_CR40","doi-asserted-by":"publisher","first-page":"26718","DOI":"10.18632\/oncotarget.14957","volume":"8","author":"Y Tao","year":"2017","unstructured":"Tao Y, Yang G, Yang H, Song D, Hu L, Xie B, et al. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 2017;8:26718\u201331.","journal-title":"Oncotarget"},{"key":"935_CR41","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.18632\/oncotarget.1740","volume":"5","author":"A Kassambara","year":"2014","unstructured":"Kassambara A, Gourzones-Dmitriev C, Sahota S, R\u00e8me T, Moreaux J, Goldschmidt H, et al. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget. 2014;5:2487\u201398.","journal-title":"Oncotarget"},{"key":"935_CR42","doi-asserted-by":"crossref","unstructured":"Ali JYH, Fitieh AM, Ismail IH The role of DNA repair in genomic instability of multiple myeloma. Int J Mol Sci. 2022;23:5688.","DOI":"10.3390\/ijms23105688"},{"key":"935_CR43","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3324\/haematol.2021.279360","volume":"107","author":"N Giesen","year":"2022","unstructured":"Giesen N, Paramasivam N, Toprak UH, Huebschmann D, Xu J, Uhrig S, et al. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica. 2022;107:1891\u2013901.","journal-title":"Haematologica"},{"key":"935_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","volume":"123","author":"F Maura","year":"2022","unstructured":"Maura F, Boyle EM, Rustad EH, Ashby C, Kaminetzky D, Bruno B, et al. Chromothripsis as a pathogenic driver of multiple myeloma. Semin Cell Dev Biol. 2022;123:115\u201323.","journal-title":"Semin Cell Dev Biol"},{"key":"935_CR45","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/cancers13030504","volume":"13","author":"T Saitoh","year":"2021","unstructured":"Saitoh T, Oda T. DNA damage response in multiple myeloma: the role of the tumor microenvironment. Cancers. 2021;13:504.","journal-title":"Cancers"},{"key":"935_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00576-3","volume":"12","author":"CY Soekojo","year":"2022","unstructured":"Soekojo CY, Chung T-H, Furqan MS, Chng WJ. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022;12:24.","journal-title":"Blood Cancer J"},{"key":"935_CR47","doi-asserted-by":"crossref","unstructured":"Ashwell S. Checkpoint kinase and Wee1 inhibitors as anticancer therapeutics. In: Kelley MR, editor. DNA repair in cancer therapy. San Diego: Academic; 2012; 211\u2013341.","DOI":"10.1016\/B978-0-12-384999-1.10010-1"},{"key":"935_CR48","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","volume":"37","author":"CJ Matheson","year":"2016","unstructured":"Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharm Sci. 2016;37:872\u201381.","journal-title":"Trends Pharm Sci"},{"key":"935_CR49","first-page":"1","volume":"2018","author":"D Chen","year":"2018","unstructured":"Chen D, Lin X, Gao J, Shen L, Li Z, Dong B, et al. Wee1 inhibitor AZD1775 combined with cisplatin potentiates anticancer activity against gastric cancer by increasing DNA damage and cell apoptosis. Biomed Res Int. 2018;2018:1\u201310.","journal-title":"Biomed Res Int"},{"key":"935_CR50","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-19-3373","volume":"26","author":"L Yang","year":"2020","unstructured":"Yang L, Shen C, Pettit CJ, Li T, Hu AJ, Miller ED, et al. Wee1 kinase inhibitor AZD1775 effectively sensitizes esophageal cancer to radiotherapy. Clin Cancer Res. 2020;26:3740\u201350.","journal-title":"Clin Cancer Res"},{"key":"935_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:281\u201392.","journal-title":"Lancet"},{"key":"935_CR52","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10120-021-01176-7","volume":"24","author":"M-H Jin","year":"2021","unstructured":"Jin M-H, Nam A-R, Bang J-H, Oh K-S, Seo H-R, Kim J-M, et al. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Cancer. 2021;24:1003\u201320.","journal-title":"Gastric Cancer"},{"key":"935_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01098-8","volume":"23","author":"A Kong","year":"2021","unstructured":"Kong A, Mehanna H. WEE1 Inhibitor: Clinical development. Curr Oncol Rep. 2021;23:107.","journal-title":"Curr Oncol Rep."},{"key":"935_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nmeth.1282","volume":"6","author":"J Wu","year":"2009","unstructured":"Wu J, Vallenius T, Ovaska K, Westermarck J, M\u00e4kel\u00e4 TP, Hautaniemi S. Integrated network analysis platform for protein-protein interactions. Nat Methods. 2009;6:75\u20137.","journal-title":"Nat Methods"},{"key":"935_CR55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/nar\/gkg034","volume":"31","author":"C von Mering","year":"2003","unstructured":"von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31:258\u201361.","journal-title":"Nucleic Acids Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00935-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00935-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00935-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T06:02:46Z","timestamp":1730700166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00935-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00935-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.04.05.535155","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SZU: Research funding: Amgen, BMS\/Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, Takeda. Consulting\/Advisory Board: Abbvie, Amgen, BMS, Celgene, Genentech, Gilead, GSK, Janssen, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}